Jupiter Neurosciences, INC 10-Q quarterly reports

Jupiter Neurosciences reported a net loss of $4.34 million for the first half of 2026, with ongoing concerns about its ability to continue as a going concern, despite a new licensing agreement for ALA-002.

Jupiter Neurosciences reported a wider net loss for Q1 2026, driven by increased general and administrative expenses, while R&D costs decreased.

Jupiter Neurosciences reports significant losses and negative cash flow, raising substantial doubt about its ability to continue as a going concern, despite strategic product development and new financing efforts.

Jupiter Neurosciences reported a significantly widened net loss in Q2 2025, driven by increased R&D and G&A expenses, while advancing its JOTROL clinical program and Nugevia supplement launch.

Jupiter Neurosciences reports its Q1 2025 financial results, focusing on research and development, particularly for its Parkinson's disease program.

Jupiter Neurosciences, a clinical-stage pharmaceutical company, released its Q3 2024 results, detailing financial performance, strategic agreements in Asia, and the closing of its initial public offering.